CAR-T therapy targeting CD19 (CART19, CTL019) has been established in heavily treated acute lymphocyte leukemia (ALL) patients because of high CR rates and durable effects in limited numbers of patients [65]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.